GlassScriptPhysician profile
Nicolas Kuritzky
NPI 1013935477
$6,441.82
in general payments reported to CMS, 2019-2025
43 companies · $721 in 2025
The $721 reported for 2025 was more than what 80% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $251 · 2021: $1,011 · 2022: $2,434 · 2023: $1,021 · 2024: $668 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $1,882.78 | 2021-2025 | Optune, Optune Gio |
| Sumitomo Pharma America, INC. | $668.12 | 2023-2025 | Orgovyx |
| Amgen INC. | $419.70 | 2019-2022 | |
| Pfizer INC. | $373.44 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $341.83 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Boston Scientific Corporation | $265.70 | 2022-2025 | Spaceoar Vue System - 10ml |
| Astrazeneca Pharmaceuticals LP | $238.24 | 2019-2023 | Imfinzi, Enhertu, Calquence |
| Myovant Sciences INC. | $207.20 | 2021-2022 | |
| Seagen INC. | $206.08 | 2020-2022 | |
| Myriad Genetic Laboratories, INC. | $194.13 | 2023 | Prolaris |
| Novartis Pharmaceuticals Corporation | $155.73 | 2019-2025 | |
| Gt Medical Technologies, INC | $141.08 | 2024-2025 | Gammatile |
| Sirtex Medical INC | $138.10 | 2019-2022 | |
| Tempus Ai, INC | $137.86 | 2025 | Xt Cdx |
| Pharmacyclics LLC, An Abbvie Company | $85.41 | 2021-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $75.92 | 2020-2022 | |
| Incyte Corporation | $68.28 | 2021-2023 | Monjuvi, Pemazyre, Jakafi |
| Eisai INC. | $62.56 | 2021-2022 | |
| Daiichi Sankyo INC. | $57.52 | 2020-2022 | |
| Janssen Biotech, INC. | $56.56 | 2021-2025 | Rybrevant |
| Siemens Medical Solutions USA, INC. | $51.79 | 2021-2023 | Aria Radiation Therapy Management Software |
| E.R. Squibb & Sons, L.L.C. | $51.27 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.62 | 2024-2025 | Fruzaqla |
| Emd Serono, INC. | $42.39 | 2019 | |
| Viewray Technologies INC | $40.88 | 2021 | |
| Abbvie INC. | $37.85 | 2019-2021 | |
| Reflexion Medical, INC. | $36.29 | 2023 | Reflexion Medical Radiotherapy System |
| Celgene Corporation | $35.70 | 2020-2021 | |
| Gilead Sciences, INC. | $34.80 | 2022 | |
| Sun Pharmaceutical Industries INC. | $32.00 | 2022 | |
| Glaxosmithkline, LLC. | $26.29 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.61 | 2025 | |
| Foundation Medicine, INC. | $21.89 | 2019 | |
| Elekta, INC. | $21.85 | 2022 | |
| Kyowa Kirin, INC. | $20.47 | 2021 | |
| Exelixis INC. | $20.33 | 2023 | Cabometyx |
| Ambu INC. | $20.03 | 2021 | |
| Deciphera Pharmaceuticals INC. | $20.00 | 2021 | |
| Morphosys, US INC. | $19.19 | 2021 | |
| Sobi, INC | $18.93 | 2023 | |
| Lilly USA, LLC | $17.52 | 2023 | Verzenio, Jaypirca, Retevmo |
| Dendreon Pharmaceuticals LLC | $15.22 | 2025 | Provenge |
| Eusa Pharma (US) LLC | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Kuritzky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.